Margin beat masks consumer healthcare turnaround pending

Delivered ₹4,337.9 Cr, +17.3% YoY — exactly matched

Delivered 27.1%, +210 bps YoY — beat upper end by 60 bps

CH delivered ₹229 Cr, slower growth due to category headwind — missed

Delivered ₹716.1 Cr, +37.7% YoY — exactly matched

Reported ₹680 Cr, +33% YoY — on track for double growth target

Delivered 72.2%, +90 bps YoY, beat 71% floor

Prior guidance 25.5–26.5%, Q2 achieved 27.1%. Driven by gross margin expansion 72.2% and operating leverage.

Guidance promised high single-digit to double-digit from Q2. Delivered slower growth due to category headwind. Management explicitly 'unhappy'.

Effective tax rate rose to 24% from 17.1% due to tax exemption expiry, compressing PAT by 690 bps, unguided headwind.

Q2 +33% YoY, tracking towards FY27 double-growth target. BSV specialty brands +34%, Mankind International +29%.

Guidance 20% growth; actual 30% driven by BSV (+34%), Mankind International (+29%). Currency benefit supports upward delta vs guidance.

27% is high-end guidance run. Operating leverage will support future expansion, but management cautious on quantifying peak level.

Yes, legacy shows 1.3–1.4x IPM beat. Management confident correction will resume, but conceded recent quarters were weak.

R&D guidance 2.8% to 3% of revenue, FY27 upper end. ACTx is early-stage, funding €48M committed through FY28, no material dilution yet.

Management unhappy with CH performance. E-commerce growing 100%, but overall segment weak. Recovery expected FY28, no firm timeline.

Upward 20–25% growth in mandate brands over 4 quarters. Chronic specialty brands (Anti-D, Foligraf) showing 30–40% growth. Momentum sustained.

Q2 base always higher, chronic margin ~37%. Goal is 100–200 bps annual expansion. Realistic ceiling 50% given market dynamics.

OTC CAGR lagging. New brand strategy: shift successful OTC products to prescription (Gas-O-Fast), then back to consumer. Limited GLP-1 color given.

Hospital growth broad-based, but earlier over-indexed to Tier-2 to Tier-6. Now shifting to Tier-1 and metros. Long-term growth potential sustainable.

UCPMP guideline voluntary so far, been preparing 3–4 years. Confident of compliance with government's future statutory rules; no material margin impact expected.

H1 FY27 +17.3% YoY on base effects. Full-year assumes growth above 12–13% IPM rate. Consumer HC turnaround needed for beat.

Q2 beat 60 bps above upper end. Driven by gross margin expansion and operating leverage. Sustainability depends on chronic share growth offsetting CH mix headwind.

Price increases and chronic mix expansion offset West Asia headwind. Outlook stable subject to FX and input cost dynamics.

H1 FY27 ₹214 Cr capex. Full-year tracking below guidance. Capacity expansion for chronic and specialty therapies underway.

Consumer Healthcare delivered ₹229 Cr with slower growth vs prior guidance of 'high single-digit to double-digit from Q2'. Management acknowledged being 'unhappy'. E-commerce growing 100%, but base offtake weak.

Effective tax rate jumped from 17.1% to 24% in H1 FY27 due to expiry of corporate tax exemption. Impact ~₹180+ Cr on full-year PAT, unguided headwind.

Chronic therapies expanding to 50% of domestic portfolio (from current 37%) over 4–5 years. Chronic margin (~37%) below acute specialty (BSV ~28% margin), so mix shift could compress overall EBITDA margin.

India pharma market (IPM) growing 12–13% per annum. Mankind targeting 11–12% CAGR in India domestic, slightly below market. Acute therapies growth lags, suggesting pricing or volume compression in competitive segments.

UCPMP (Uniform Code of Pharmaceutical Marketing Practices) marketing guideline Supreme Court hearing Jan 29, 2027. Outcome could restrict promotional spend or impose stricter compliance, impacting sales execution.